Qualification of stride velocity endpoint in Duchenne Muscular Dystrophy

By Katherine Bricceno and Daniela Drago2021-10-01T10:39:00

In April 2019, the Committee for Medicinal Products for Human Use (CHMP) issued a qualification opinion on stride velocity as an endpoint in clinical studies of medicines for the treatment of Duchenne Muscular Dystrophy (DMD).[1] Mutations in the dystrophin gene cause this inherited, x-linked disorder which causes progressive muscle weakness ...

How to read this article

Thank you for visiting Regulatory Rapporteur, you have now used up your free accesses.

To continuing reading you can register for free, join TOPRA, or if you are a member login now.

REGISTER FOR FREE

1. Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

Create your own library to save your favourite content.
Sign up for Regulatory Rapporteur email newsletters.

Create a free account

Members login

2. Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.

JOIN TOPRA

3. TOPRA membership

Become a TOPRA member and join our global regulatory affairs community.

Great savings on our events and training.
Be part of our dynamic international community.
Contribute to the profession.
Grow your skills and knowledge.
Take your career to the next level.

Become a member